Wegovy 2,4 mg
€180
Wegovy 2,4 mg rappresenta un potente strumento nella lotta contro l'obesitàsostenuta dalla scienza e mondo reale successo. Se siete pronti a prendere il controllo del vostro peso, parlare con un professionista sanitario, oggi per esplorare se questo farmaco è giusto per te. Ricordate, il cambiamento sostenibile deriva da scelte consapevoli e supporto continuo.
Descrizione Del Prodotto
Wegovy 2,4 mg
Wegovy 2.4 mg (semaglutide) is an FDA-approved prescription injectable medication designed for chronic weight management in adults with obesity or overweight conditions accompanied by weight-related medical issues. Representing the maximum therapeutic maintenance dose, Wegovy 2.4 mg is administered once weekly alongside a reduced-calorie meal plan and increased physical activity to support long-term weight loss.
How Wegovy 2.4 mg Works
Wegovy belongs to a class of medications called glucagon-like peptide-1 (GLP-1) receptor agonists. Semaglutide mimics the naturally occurring GLP-1 hormone produced in the intestines, directly targeting areas of the brain that regulate appetite and food intake.
-
Satiety Enhancement: Promotes a feeling of fullness after meals, reducing overall caloric intake and cravings.
-
Ritardo nello svuotamento gastrico: Slows the rate at which food leaves the stomach, helping maintain fullness longer.
-
Cardiovascular Benefits: Reduces the risk of major adverse cardiovascular events in adults with established cardiovascular disease and obesity.
Linee guida per il dosaggio e la somministrazione
Wegovy 2.4 mg is the final maintenance dose reached after a gradual dose-escalation schedule designed to minimize gastrointestinal side effects.
| Parametro chiave | Raccomandazione clinica |
| Amministrazione | Subcutaneous injection into the abdomen, thigh, or upper arm once weekly. |
| Pianificazione | Administer on the same day each week, at any time of day, with or without food. |
| Dose Progression | Reached after completing 16 weeks of step-up dosing (0.25 mg to 1.7 mg). |
Note: Never increase your dosage or alter your administration schedule without explicit medical supervision from your healthcare provider.
Possibili effetti collaterali e avvertenze di sicurezza
While Wegovy 2.4 mg demonstrates strong clinical efficacy for weight loss, awareness of potential side effects and health precautions is essential.
Effetti Collaterali Comuni
-
Nausea, vomito e diarrea
-
Constipation, stomach pain, and heartburn
-
Fatigue, headache, and dizziness
-
Mild injection site reactions
Serious Warnings and Precautions
-
Thyroid Tumor Risk: Controindicato nei pazienti con anamnesi personale o familiare di carcinoma midollare della tiroide (CMT) o sindrome da neoplasia endocrina multipla di tipo 2 (MEN 2).
-
Pancreatite acuta: Monitor for persistent, severe abdominal pain that radiates to the back.
-
Rischio di ipoglicemia: Increased rischio of low blood sugar when used in combination with insulin secretagogues or insulin.



